The News

Stay up to date with the latest news

Press Releases

TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases
November 14, 2023
TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
January 9, 2023
TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases
March 8, 2022
TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
January 6, 2022
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
June 22, 2021

In the News

TRexBio: restoring tissue immune homeostasis via Treg modulation
June 19, 2023 – BioCentury
Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
January 9, 2023 – Endpoints News
Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration
January 10, 2022 – Genetic Engineering & Biotechnology News
T_reg engineers take aim at autoimmunity
November 9, 2021 – Nature Biotechnology
Biotech TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding
Jun 22, 2021 – Fierce Biotch
TRexBio Chomps Down on $59 Million Series A for Immunobiology
Jun 22, 2021 – BioSpace
Big Pharma backers jump on board ‘Treg’ cartographer’s lead round with up to six candidates in the pipe
June 22, 2021 – Endpoints News